← 홈

ADC · 다발성 골수종

16개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 16개
ADCCBiologicChristopher StrousePhase 2

Sirolimus (Sirolimus)

Multiple Myeloma · FRα

#FR#ADC#Phase2#인기#항체약물접합체+3
효능 ORR 9%임상시험 81상태 DISCONTINUED
ADCBiologicPfizerPhase 3

Iberdomide (Iberdomide)

Multiple Myeloma · FRα

#FR#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 92.9%임상시험 47상태 RECRUITING
ADCBiologicSanofiPhase 2

Belumosudil (Belumosudil)

Plasma Cell Myeloma Refractory · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 74%임상시험 38상태 RECRUITING
ADCBiologicstaleCanadian Myeloma Research GroupPhase 2

GSK2857916 with Pomalidomide and Dexamethasone (GSK2857916 with Pomalidomide and Dexamethasone)

Relapsed and/or Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 100%임상시험 7상태 RECRUITING
ADCBiologicstaleSanofiPhase 2

Pegenzileukin (Pegenzileukin)

Plasma Cell Myeloma Refractory · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 92.9%임상시험 5상태 RECRUITING
ADCBiologicstaleSanofiPhase 2

SAR439459 (SAR439459)

Plasma Cell Myeloma Refractory · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 4상태 RECRUITING
ADCBiologicstaleMultiple Myeloma Research Conso…Phase 2

Selinexor, dexamethasone, ixazomib, pomalidomide (Selinexor, dexamethasone, ixazomib, pomalidomide)

Relapsed Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 3상태 ACTIVE
ADCBiologicstaleMultiple Myeloma Research Conso…Phase 2

Venetoclax, dexamethasone, ixazomib, pomalidomide (Venetoclax, dexamethasone, ixazomib, pomalidomide)

Relapsed Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 3상태 ACTIVE
ADCBiologicstaleGSKPhase 2

belantamab mafodotin (Blenrep, GSK2857916, Belantamab Mafodotin, Cyclophosphamide and Dexamethasone)

Relapsed/Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 3%임상시험 2상태 DISCONTINUED
ADCBiologicstaleGSKPhase 2

belantamab mafodotin (Blenrep, GSK2857916, Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide)

Relapsed Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 2상태 ACTIVE
ADCBiologicstaleMultiple Myeloma Research Conso…Phase 2

Abemaciclib, dexamethasone, ixazomib, pomalidomide (Abemaciclib, dexamethasone, ixazomib, pomalidomide)

Relapsed Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 ACTIVE
ADCBiologicstaleMultiple Myeloma Research Conso…Phase 2

Cobimetinib, dexamethasone, ixazomib, pomalidomide (Cobimetinib, dexamethasone, ixazomib, pomalidomide)

Relapsed Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 ACTIVE
ADCBiologicstaleMedImmune LLCPhase 1

antibody drug conjugate (Dose Escalation, MEDI2228, ADC, Dose Escalation, MEDI2228, ADC (antibody drug conjugate))

Relapsed/Refractory Multiple Myeloma · FRα

#FR#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 ACTIVE
ADCBiologicstaleMedImmune LLCPhase 1

antibody drug conjugate (Dose Expansion, MEDI2228, ADC, Dose Expansion, MEDI2228, ADC (antibody drug conjugate))

Relapsed/Refractory Multiple Myeloma · FRα

#FR#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 ACTIVE
ADCBiologicstaleMultiple Myeloma Research Conso…Phase 2

Enasidenib, dexamethasone, ixazomib, pomalidomide (Enasidenib, dexamethasone, ixazomib, pomalidomide)

Relapsed Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 ACTIVE
ADCBiologicstaleMultiple Myeloma Research Conso…Phase 2

Erdafitinib, dexamethasone, ixazomib, pomalidomide (Erdafitinib, dexamethasone, ixazomib, pomalidomide)

Relapsed Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 ACTIVE